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Abstract
Purpose Cicatrising conjunctival disorders
are uncommon, and are difficult to diagnose
and manage. This study was designed to
assess the annual incidence and underlying
diagnosis of patients with cicatrising
conjunctivitis (CC) within the United
Kingdom.
Methods Clinical data of newly diagnosed
cases of CC were reported via the British
Ophthalmological Surveillance Unit at
diagnosis and at 12 months follow-up.
Results A total of 50 (61%) ocular mucous
membrane pemphigoid (OcMMP), 16 (20%)
Stevens–Johnson syndrome/toxic epidermal
necrolysis (SJS-TEN) and 16 (20%) other
causes of CC, equating to an incidence of 0.8,
0.2, and 0.2 per million, respectively, were
reported. Although diagnosis of SJS-TEN
was usually within a median of 7 days of
symptom-onset, that for OcMMP and other
CC was a median 225 days for both. At
diagnosis, 64/163 (39%) eyes had moderate/
severe conjunctival inflammation, and
102/164 (62%) had symblepharon formation.
Although 43/82 (52%) patients were
commenced on immunosuppression or had
this therapy modified, at follow-up there was
an increase in the number of symblepharon,
despite control of inflammation (Po0.001).
Mortality only occurred in the SJS-TEN
group (4/16 (25%)).
Conclusion CC has a substantial morbidity
and for non-SJS-TEN causes, diagnosis is
frequently delayed. The proportion of
patients given immunosuppressive therapy to
prevent disease progression may be less than
optimal. These data highlight the need for
developing patient access to specialist-
designated centres with expertise in CC.
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Introduction
Cicatrising conjunctivitis (CC) is a rare but sight-
threatening group of disorders for which early
diagnosis and appropriate treatment are
essential.1 Conjunctival scarring and chronic
inflammation lead to persistent ocular discomfort,
limbitis, limbal epithelial stem cell deficiency, and
ocular surface failure with subsequent blinding
keratopathy. Although the majority of cases have
mucous membrane pemphigoid (MMP), a
systemic, ‘type 2’ autoimmune disease2 with
ocular involvement in about 70% of cases (ocular
MMP, OcMMP),3 other causes of either slowly
progressive or progressive CC include atopic
keratoconjunctivitis (AKC), Sjo¨gren’s syndrome
(SS), ocular rosacea, Stevens–Johnson Syndrome
(SJS) and its more severe form, toxic epidermal
necrolysis (TEN), drug-induced conjunctival
cicatrisation (DICC), graft vs host disease
(GVHD), linear IgA disease, epidermolysis
bullosa acquisita (EBA), and mucocutaneous
paraneoplastic disorders, some of which can be
clinically indistinguishable from OcMMP.1,4
Although early diagnosis and treatment are
important,1 the diseases are rare and most
individual clinicians see few cases. This may
lead to failure to recognise the clinical features
in the early stages of disease and result in
delayed or suboptimal treatment.
The incidence of CC is largely unknown.
Several European studies have attempted to
measure the incidence of the systemic diseases
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that may cause CC. A prospective study of patients
presenting to dermatologists with subepidermal bullous
diseases in three French regions showed a 1.13 per
million incidence of MMP.5 In a separate French study,
the incidence of linear IgA disease and EBA were
reported as 0.48 and 0.17–0.26 per million, respectively;5
a slightly lower incidence of the same diseases was
reported in a German study,6 highlighting the likelihood
of regional variance, possibly due to genetic and
environmental influences. For the SJS-TEN spectrum of
disorders, the annualised incidence in Germany has been
estimated as 1.89 per million,7 with ocular involvement
in circa 70% and 50% of cases, respectively,8 and a
mortality of 25%.7
There are no epidemiological data regarding
conjunctival scarring disorders in UK. Given the chronic
nature of CC and the impact these patients have on
clinical service provision, frequently requiring lifelong
follow-up and resource thirsty management strategies, a
national survey was undertaken in collaboration with the
British Ophthalmological Surveillance Unit (BOSU)
using their methodology.9 Our study specifically aimed
to establish (i) the incidence of CC within the United
Kingdom, (ii) assess patients’ clinical features at the time
of diagnosis and at 12 months follow-up, and (iii) to map
the distribution of patients as a first step in planning of a
network of collaborating specialist clinics within the
United Kingdom.
Materials and methods
Cases of CC were collected prospectively through the
BOSU, using previously described methodology,9 from
January 2008 to December 2008. Ophthalmologists were
asked to report cases of newly diagnosed CC, defined
as conjunctival inflammation associated with scarring
(eg, OcMMP, AKC, ocular rosacea, SS, DICC, GVHD,
linear IgA Disease, EBA, ocular surface squamous
neoplasia (OSSN), or any case of SJS-TEN). Patients with
a history of trachoma, an acute infectious membranous
conjunctivitis or trauma (chemical, radiation, heat,
mechanical, surgical) were excluded. Reporters
completed datasheets relating to demographics and
clinical findings at initial presentation and after 12
months follow-up (or the closest clinical review date to
12 months).
For causes of CC other than MMP, a combination
of the medical history, ocular and systemic clinical
signs, histopathology, or immunopathology where
available, were used to establish the diagnosis.
For purposes of this study, proven OcMMP cases
were defined as those having both a positive direct
immunofluorescence (DIF) biopsy result (IgG, IgA, C3
deposition along the basement membrane zone) from
any site (eye or extra-ocular), in addition to having
the characteristic clinical phenotype for ocular disease
(a typical conjunctival fibrosis pattern), with or without
MMP diagnosed at an extra-ocular site. Presumed
OcMMP cases were defined using the same criteria as for
proven OcMMP but with negative, unperformed, or
missing DIF biopsy results in the absence of other
disorders causing progressive CC including DICC, AKC,
SS, and SJS-TEN.10 Staging of OcMMP was determined
by Mondino and Brown,11 and Foster systems.12
Only patients resident in the United Kingdom with
a new diagnosis of CC made within the 12 months
surveillance period (2008) were included in this study.
Using mid-2008 population estimates for the 12 UK
regions (Office of National Statistics, www.statistics.
gov.uk), incidence figures were calculated for each
disorder causing CC, and an analysis of short-term
(12 months) progression and outcomes was performed.
The study was approved by the BOSU Scientific
Committee of the Royal College of Ophthalmologists,
and the Multicentre Research Ethics Committee, London
(07/MREC02/41). The study was conducted according to
the Tenets of the Declaration of Helsinki. Where relevant,
data were analysed using the w2 test for association with
the Yates continuity correction for small numbers using
SPSS version 15 for Windows (Chicago, IL, USA).
Results
Reports of cases
A total of 124 reports of CC and/or SJS-TEN from 31
different hospitals were received via BOSU. The BOSU
report card return rate for this period was 77% (BOSU
Personal communication, October 2010). Overall 82 of
124 (66%) were eligible cases, diagnosed as OcMMP
(n¼ 50), SJS-TEN (n¼ 16), or other diseases causing CC
(‘Other CC’) (n¼ 16). Of the 42/124 ‘rejected’ reported
cases, 17 (14%) presented before the study period, clinical
data were not received for 13 (11%), 7 (6%) were
duplicate reports, and 5 (4%) were reported in error.
Twelve months follow-up data were available for 40/50
(80%) of the OcMMP cases, 9/16 (56%) of the SJS-TEN
cases, and 13/16 (81%) of the Other CC cases group.
Incidence
The overall minimum incidence of CC in the United
Kingdom was calculated as 1.3 per million UK
population, but with geographical variance: 0.1 for
north west England to 4.2 for west Midlands (Figure 1).
Upon analysing incidence statistics for each CC category,
the minimum incidence per million population was
calculated as 0.8 OcMMP (0.6 biopsy-proven, 0.2 presumed),
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0.2 SJS-TEN, and 0.2 Other CC. A synopsis of the
incidence variance according to UK region is provided
in Figure 1.
Causes of CC
Of the 50 cases of OcMMP, almost half (21/50 (42%)) had
not had a tissue biopsy or had biopsy results that were
unavailable (n¼ 4); this group included 12 patients with
extra-ocular manifestations of the disease. In all, 22 (44%)
were DIF biopsy-positive (conjunctiva, n¼ 13; other sites,
n¼ 9) and seven (14%) had a negative biopsy. Indirect
immunofluorescence (IIF) studies were positive in 4 of 12
patients, all of whom were DIF biopsy-positive.
Overall, 16 cases of SJS-TEN were reported of whom
conjunctival scarring or acute conjunctival adhesion
formation was present in 4/5 (80%) of SJS and 6/11 (55%)
of TEN cases. Concurrent skin manifestations, oral
disease, or other mucous membrane involvement were
common (SJS, 14/16 (88%); TEN, 10/16 (63%)).
Of the remaining 16 cases, CC had been caused by
drugs (n¼ 3), ocular rosacea (n¼ 3), GVHD (n¼ 2), lichen
planus/sclerosis (n¼ 2), AKC (n¼ 3), OSSN (n¼ 1),
linear IgA disease (n¼ 1), or SS (n¼ 1), with systemic
manifestations in 8/16 (50%; skin (n¼ 6), mouth (n¼ 2),
other mucous membranes (n¼ 2)).
Diagnostic delay
Diagnosis of SJS-TEN was significantly quicker (median
7 (range 1–120) days) than for OcMMP or other causes of
CC, probably because of its acute presentation vs the
more insidious presentations for OcMMP and Other CC
(P¼ 0.01). Among patients with OcMMP, absence of
preceding extra-ocular manifestations was significantly
associated with diagnostic delay (P¼ 0.019) (Table 1).
Ocular Mucous Membrane Pemphigoid
West Midlands 9 5,411,100 1.6
Yorkshire and the Humber 6 5,213,200 1.1
South West England 6 5,209,200 1.1
South East England 9 8,380,100 1.0
Greater London 8 7,619,800 1.0
East of England 6 5,728,700 1.0
North East England 2 2,575,500 0.7
Northern Ireland 1 1,775,000 0.5
Scotland 2 5,168,500 0.3
North West England 1 6,875,700 0.1
East Midlands 0 4,433,000 0.0
Wales 0 2,993,400 0.0
UNITED KINGDOM 50 61,383,200 0.8
Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis
West Midlands 7 5,411,100 1.2 
Wales 1 2,993,400 0.3 
Greater London 2 7,619,800 0.2 
East Midlands 1 4,433,000 0.2
South East England 1 8,380,100 0.1 
East of England 1 5,728,700 0.1
Yorkshire and the Humber 1 5,213,200 0.1
Scotland 1 5,168,500 0.1 
North West England 0 6,875,700 0.0
South West England 0 5,209,200 0.0
North East England 0 2,575,500 0.0
Northern Ireland 0 1,775,000 0.0
Unknown 1 
UNITED KINGDOM 16 61,383,200 0.2 
Other Causes of Cicatrising Conjunctivitis
West Midlands 7 5,411,100 1.2
Wales 2 2,993,400 0.6
Greater London 3 7,619,800 0.3
Yorkshire and the Humber 2 5,213,200 0.3
South East England 1 8,380,100 0.1
East of England 1 5,728,700 0.1
North West England 0 6,875,700 0.0
South West England 0 5,209,200 0.0
Scotland 0 5,168,500 0.0
East Midlands 0 4,433,000 0.0
North East England 0 2,575,500 0.0
Northern Ireland 0 1,775,000 0.0
UNITED KINGDOM 16 61,383,200 0.2
Cicatrising Conjunctivitis (All Causes)
West Midlands 23 5,411,100 4.2
Greater London 13 7,619,800 1.7
Yorkshire and the Humber 9 5,213,200 1.7
South East England 11 8,380,100 1.3
East of England 8 5,728,700 1.3
South West England 6 5,209,200 1.1
Wales 3 2,993,400 1.0
North East England 2 2,575,500 0.7
Scotland 3 5,168,500 0.5
Northern Ireland 1 1,775,000 0.5
East Midlands 1 4,433,000 0.2
North West England 1 6,875,700 0.1
Unknown 1
UNITED KINGDOM 76 61,383,200 1.3
CASES INCIDENCE per millionPOPULATIONUK REGIONS
Figure 1 Geographical distribution of newly reported cases of CC in the United Kingdom.
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Patient characteristics
Demographic data are detailed in Table 1. The median
age (range) for patients with OcMMP and Other CC was
71 (20–90) and 67.5 (14–89) years, respectively, whereas
for SJS-TEN patients was 42 (5–100) years. Interestingly, a
slight predominance of male patients in OcMMP or
Other CC contrasted with the female predominance in
SJS-TEN (12/16 (75%)). Among patients with OcMMP,
8/50 (16%) had other systemic autoimmune disease
(eg, rheumatoid arthritis) and about a third had ocular
comorbidity (eg, glaucoma, cataract).
Clinical features at diagnosis
A total of 34 of 150 (23%) eyes had a best-corrected visual
acuity (VA) of o6/18 at the time of diagnosis. Although
symblepharon (101/164 (62%)), trichiasis (57/164 (35%)),
entropion (37/164 (23%)), and punctate keratitis (68/164
(41%)) were the most common presenting clinical signs
(Table 2) specifically in OcMMP and Other CC eyes,
mild/moderate ocular surface inflammation ((29/32)
90%) was the principal clinical finding in ocular SJS-TEN.
Overall, abnormalities of the tear film or dry eye were
found in 106/156 (67.9%) eyes, whereas limbitis (20/164
(12%)), persistent epithelial defects (9/164 (5%)),
keratinisation (26/164 (16%)) or corneal involvement
(scarring/vascularisation (12/164 (7%)), microbial
keratitis (22/164 (13%))) were less common. OcMMP
staging (Table 3) was more advanced when graded by
Foster12 (stage III/IV 71/100 (71%)) vs Mondino11 (stage
III/IV 27/94 (29%)).
Treatments received before diagnosis
At the time of diagnosis, immunosuppression was
being received by 5/50 (10%) of OcMMP patients
who had coexisting ancillary autoimmune disease,
9/16 (56%) of SJS-TEN, and none of the cases of Other
CC. The burns intensivists/dermatologists had initiated
Table 1 Conjunctival cicatrisation: summary of incidence, diagnostic delay and patient characteristics
Ocular mucous
membrane pemphigoid
(OcMMP)
Stevens-Johnson
syndrome/toxic epidermal
necrolysis (SJS-TEN)
Other cicatrising
conjunctivitis
(Other CC)a
Number of reported cases 50 16 16
Incidence per million (assuming UK
population of 61 383 200)
0.8 0.2 0.2
Diagnostic delay
Range 7–3650 1–120 16–7300
Median 225 7 225
Mean (±SD) 605 (±897) 18.6 (±31.07) 751 (±1779)
With preceding extra-
ocular signs, n¼ 21b
Without preceding extra-
ocular signs, n¼ 26c
Range 21–1155 7–3650
Median 180 405
Mean (±SD) 292d (±326) 915d (±1131)
Patient characteristics
Age, mean/median (range) years 67.1/71 (20–90) 40/42 (5–100) 60.8/67.5 (14–89)
Gender, male : female (%) 29 : 21 (58 : 42) 4 : 12 (25 : 75) 9 : 7 (56 : 44)
Extra-ocular features, n (%) 32 (64) 16 (100) 8 (50)
Oral 28 (56) 14 (88) 2 (13)
Skin 10 (20) 16 (100) 6 (38)
Other mucous membranes 6 (12) 10 (63) 2 (13)
Autoimmune disease (%)e 8 (16) 0 1 (6)
Ocular comorbidity (%)f 17 (34) 0 5 (31)
aOther causes of cicatrising conjunctivitis were: drug toxicity (3), ocular rosacea (3), atopic conjunctivitis (3), graft vs host disease (2), lichen planus/lichen
sclerosis (2), ocular surface squamous neoplasia (1), linear IgA disease (1),and Sjo¨gren’s syndrome (1).
bExcluding two with unknown symptom duration.
cExcluding one with unknown symptom duration.
dAbsence of preceding extra-ocular signs was significantly associated with diagnostic delay (t¼ 2.4391, P¼ 0.019).
eRheumatoid arthritis (RA) (2), RA and ulcerative colitis (2), RA and pernicious anaemia (2), RA and hypothyroidism (2), hypothyroidism (5),
Crohn’s disease and Grave’s disease (2), Sjo¨gren’s syndrome (2). All but one of these patients had OcMMP.
fCataract (20), glaucoma (9), amblyopia (8), maculopathy (6), retinal detachment (4), thyroid eye disease (3), chronic anterior uveitis (2), diabetic
retinopathy (2), metastatic endophthalmitis (2), recurrent herpes simplex virus ulcers (2).
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a range of strategies for the treatment of acute
or subacute SJS-TEN, including intravenous
immunoglobulins (n¼ 5), oral prednisolone (n¼ 2),
intravenous methylprednisolone (n¼ 2), cyclosporin
(n¼ 1), and infliximab (n¼ 1) before first ophthalmology
examination. Surgical intervention for hitherto
unrecognised sequelae of conjunctival scarring were
most common in the OcMMP group (OcMMP 10/50
(20%) vs SJS-TEN (0) vs Other CC (1/16 (6%)),
and this included entropion surgery (5/66 (8%)),
electrolysis (4/66 (6%)), and cryotherapy (2/66 (3%)).
Treatment given after diagnosis
Following diagnosis, more than half of the patients
(43/82 (52%)) required either initiation of immuno-
suppression or alteration of the current therapy to a
more potent regimen (step-up)13 (OcMMP 30/50 (60%),
Table 2 Cicatrising conjunctival disorders: prevalence of clinical features at diagnosis and follow up
CC category (no. of eyes) OcMMP (100) SJS-TEN (32) Other CC (32)
n (%) Diagnosis Follow-up Diagnosis Follow-up Diagnosis Follow-up
Visual acuity
6/6–6/18 80/98 (82) 57/71 (80) 13/22 (59) 10/18 (71) 23/30 (77) 21/26 (81)
6/24–6/36 8/98 (9) 5/71 (7) 4/22 (18) 0/18 (0) 3/30 (10) 2/26 (8)
6/60–3/60 3/98 (3) 3/71 (4) 1/22 (5) 0/18 (0) 3/30 (10) 3/26 (12)
o3/60 7/98 (7) 6/71 (9) 4/22 (18) 4/18 (29) 1/30 (3) 0/26 (0)
Trichiasis 46/100 (46) 37/80 (46) 2/32 (6) 7/16 (44) 9/32 (28) 9/26 (35)
Entropion 28/100 (28) 19/80 (24) 2/32 (6) 0/16 (0) 7/32 (22) 3/26 (12)
Conjunctival inflammation
Absent 26/99 (26) 57/80 (71) 3/32 (9) 12/16 (75) 3/32 (9) 21/26 (81)
Mild 33/99 (33) 17/80 (21) 18/32 (56) 2/16 (13) 16/32 (50) 4/26 (15)
Moderate 25/99 (25) 6/80 (8) 11/32 (34) 2/16 (13) 11/32 (34) 0/26 (0)
Severe 15/99 (15) 0/80 (0) 0/32 (0) 0/16 (0) 2/32 (6) 1/26 (4)
Lower fornix shrinkage
0–25% 33/94 (35) 27/76 (36) 28/32 (88) 9/16 (56) 17/32 (53) 16/24 (67)
25–50% 34/94 (36) 19/76 (25) 2/32 (6) 6/16 (38) 11/32 (34) 6/24 (25)
50–75% 16/94 (17) 16/76 (21) 2/32 (6) 0/16 (0) 2/32 (6) 2/24 (8)
75–100% 11/94 (12) 14/76 (18) 0/32 (0) 1/16 (6) 2/32 (6) 0/24 (0)
Symblepharon
Absent 14/100 (14) 10/80 (13) 20/32 (63) 2/16 (13) 9/32 (28) 6/26 (23)
Plica loss only 16/100 (16) 10/80 (13) 0/32 (0) 4/16 (25) 4/32 (13) 1/26 (4)
One symblepharon 26/100 (26) 15/80 (19) 8/32 (25) 2/16 (13) 16/32 (50) 4/26 (15)
Two or more symblephara 33/100 (33) 35/80 (44) 4/32 (13) 8/16 (50) 3/32 (9) 13/26 (50)
Ankyloblepharon 11/100 (11) 10/80 (13) 0/32 (0) 0/16 (0) 0/32 (0) 2/26 (8)
Tear film
Normal 26/92 (28) 20/76 (26) 12/32 (38) 0/16 (0) 12/32 (38) 12/24 (50)
Reduced break-up time 29/92 (32) 28/76 (37) 12/32 (38) 8/16 (50) 8/32 (25) 12/24 (50)
Dry eye 37/92 (40) 28/76 (37) 8/32 (25) 8/16 (50) 12/32 (38) 0/24 (0)
Ocular surface keratinisation
No keratinisation 81/100 (81) 69/80 (86) 28/32 (88) 10/16 (63) 29/32 (91) 21/24 (88)
Partial keratinisation 18/100 (18) 9/80 (11) 2/32 (6) 4/16 (25) 3/32 (9) 3/24 (12)
Whole-surface keratinisation 1/100 (1) 2/80 (2) 2/32 (6) 2/16 (13) 0/32 (0) 0/24 (0)
Other ocular surface signs
Punctate keratitis 43/100 (43) 30/80 (38) 8/32 (25) 5/16 (31) 17/32 (53) 10/26 (38)
Persistent epithelial defect 4/100 (4) 2/80 (3) 3/32 (9) 4/16 (25) 2/32 (6) 0/26 (0)
Limbitis 12/100 (12) 3/80 (4) 2/32 (6) 1/16 (6) 6/32 (19) 3/26 (12)
(History of) Microbial keratitis 12/100 (12) 3/80 (4) 5/32 (16) 1/16 (6) 5/32 (16) 0/26 (0)
Central opacities/neovascularisation 9/100 (9) 7/80 (9) 2/32 (6) 4/16 (25) 1/32 (3) 3/26 (12)
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SJS-TEN 10/16 (63%), Other CC 4/16 (25%)), and the
most commonly prescribed agents were glucocorticoids
(23/82 (28%)), dapsone (12/82 (15%)), mycophenolate
(12/82 (15%)), and cyclophosphamide (9/82 (11%)).
Intravenous immunoglobulin was restricted to the
SJS-TEN patients (7/16 (44%)). The most commonly
prescribed topical medications were steroids (51/82
(62%)) and lubricants ((50/82 (61%)). The distribution
of treatment strategies among all three groups is
summarised in Table 4.
Patient follow-up
For 20 patients follow-up was not available owing to
patient mortality (n¼ 4, all SJS-TEN), failure of the
reporting ophthalmologists to supply follow-up data
(n¼ 6), or patients being lost to follow-up (n¼ 10). For
the 62/82 (76%) remaining patients for whom further
data were received, the length of follow-up ranged from
116 to 657 days, with a median of 397 days.
At follow up, 88/115 (77%) of eyes had a VA of 6/18 or
better (Table 2). Although there was significantly less
conjunctival inflammation compared with diagnosis
(Po0.001) in all groups (Table 2), there was an increase
in the number of symblepharon (OcMMP 11/78 (14%),
SJS-TEN 2/16 (13%), Other CC 7/26 (27%)), indicating
progression of conjunctival cicatrisation. This was
supported by a subanalysis of the OcMMP group,
where eyes had advanced in stage according to both
Mondino- (17/66 (26%)) and Foster- (11/69 (16%))
staging systems (Table 3).
A total of 30 of 62 (48%) patients remained on
immunosuppression at the time of follow-up, of which
9 (30%) had a further ‘step-up’ of treatment during this
period; the majority of whom were in the OcMMP cohort
(Table 4). Surgical intervention was required for 15 (24%)
patients and this consisted of entropion surgery (8),
lash electrolysis (5), cryotherapy (3), amnion grafting (2),
surgical division of symblepharon (1), superficial
keratectomy (1), and tectonic corneal transplant (1).
Discussion
Incidence
This is the first study to estimate the incidence of
conjunctival scarring disorders in any country.
Limitations of the study are the 77% BOSU card return
rate and the 13 reported patients (a potential 14% loss
of incident cases) for whom no data were received.
One of the first BOSU studies14 identified a similar loss
of 9%, but the UK’s National Patient Safety Agency and
National Research Ethics Service guidelines continue to
prevent the recording of the patient hospital number on
the report card, which would overcome this problem.
The data presented in this manuscript should therefore
be considered an estimate of the minimum incidence.
Despite this limitation, the incidence of OcMMP in the
United Kingdom (0.8 per million) appears to be in
keeping with those reported in France5 and Germany.6
A total of 90% of patients with acute SJS-TEN have ocular
involvement and our incidence of 0.2 per million is lower
than those of hospitalised cases in Germany, even after
allowing for their inclusion of cases without ocular
involvement.7 This is possibly because many patients in
the United Kingdom are examined and managed by
dermatologists or Burns Unit personnel according to
local guidelines, and only those with ocular involvement
resistant to first-line treatments, are referred for specialist
ophthalmology opinion. Consistent with other studies,7
our mortality rate for SJS-TEN group was 25%. Overall,
there was considerable apparent geographical variation
in the incidence of cicatrising conjunctival disorders in
the United Kingdom, but these data are likely to reflect
either differing levels of cooperation among reporting
ophthalmologists or lack of awareness of the disease in
Table 3 Ocular mucous membrane pemphigoid: disease stage
at diagnosis and at follow-up
At diagnosis,
n (%)
At follow-up,
n (%)
Eyes 100 80
Mondino staging
Stage I 33/94 (35) 27/76 (36)
Stage II 34/94 (36) 19/76 (25)
Stage III 16/94 (17) 16/76 (21)
Stage IV 11/94 (12) 14/76 (18)
Foster staging
Stage I 8/100 (8) 5/78 (6)
Stage II 21/100 (21) 11/78 (14)
Stage III 59/100 (59) 52/78 (67)
Stage IV 12/100 (12) 10/78 (13)
Disease progression
Mondino
Worsened by at least one stage 17/66 (26)
No change 49/66 (74)
Already stage IV 8
Could not assess 6
Foster
Worsened by at least one stage 11/69 (16)
No change 58/69 (84)
Already stage IV 9
Could not assess 2
Mondino and Brown: (I) 0–25%, (II) 25–50%, (III) 50–75%, (IV) 75–100%
loss of inferior fornix. Foster: (I) subconjunctival scarring and fibrosis,
(II) fornix foreshortening of any degree, (III) presence of any degree of
symblepharon, (IV) end-stage cicatricial pemphigoid.
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the areas reporting low incidences, and possibly genetic
susceptibility due to differences in ethnic mix, rather
than environmental/geographical influences.
Diagnosis
Diagnostic delay was unusual for SJS-TEN patients, who
present with generally more acute disease. Considerable
diagnostic delay was common for the other, rarer causes
of CC together with those with OcMMP. Delays were
particularly marked in patients with no pre-existing or
coexisting extra-ocular manifestations, highlighting the
importance of considering OcMMP as a differential
diagnosis in any case of trichiasis or recurrent
conjunctivitis, and the need for performing an early
confirmatory conjunctival biopsy (with or without an
Table 4 Treatment initiated at time of diagnosis and during follow-up
CC category (no. of patients)
Ocular mucous membrane
pemphigoid (n¼ 50)
Stevens-Johnson syndrome/
toxic epidermal necrolysis
(n¼ 16)
Other cicatrising
conjunctivitis (n¼ 16)
At diagnosis,
n¼ 50
At follow-up,
n¼ 40
At diagnosis,
n¼ 16
At follow-up,
n¼ 9
At diagnosis,
n¼ 16
At follow-up,
n¼ 13
n (%) n (%) n (%) n (%) n (%) n (%)
Systemic medication
Any immunosuppressant 32 (64) 26 (65) 10 (63) 2 (22) 4 (25) 2 (15)
Corticosteroids 18 (36) 12 (30) 4 (25) 1 (11) 1 (6) 0
Dapsone 10 (20) 7 (18) 0 0 2 (13) 1 (8)
Mycophenolate 9 (18) 13 (33) 2 (13) 1 (11) 1 (6) 0
IV Methyl prednisolone 3 (6) 3 (8) 1 (6) 0 0 0
Azathioprine 6 (12) 5 (13) 0 0 0 0
Cyclophosphamide 8 (16) 4 (10) 1 (6) 0 0 1 (8)
Cyclosporin 1 (2) 0 1 (6) 0 1 (6) 0
Methotrexate 1 (2) 0 0 0 1 (6) 0
Sulphamethoxypyridazine 1 (2) 1 (3) 0 0 0 0
Doxycycline 0 0 0 0 2 (13) 0
Othera 0 0 11 (69) 2 (22) 0 0
Changes in immunosuppression
Stepped up 30 (60) 6 (15) 10 (63) 0 4 (25) 1 (8)
Stepped up then down 2 (5) 0 0
Stepped down (improvement) 4 (10) 3 (33) 1 (8)
Stepped down (refusal/
intolerance)
6 (15) 0 1 (8)
No change 15 (38) 2 (22) 1 (8)
Not given immunosuppression 7 (18) 3 (33) 9 (69)
Topical medication
Steroids 26 (52) 22 (55) 15 (94) 6 (67) 10 (63) 6 (46)
Lubricants 31b (62) 33b (83) 15 (94) 8 (89) 15 (94) 11 (85)
Otherc 9 (18) 5 (13) 8 (50) 6 (67) 5 (31) 3 (23)
Surgery during follow-up
Any surgery 12 (30) 2 (22) 1 (8)
Entropion surgery 8 (20) 0 0
Electrolysis 5 (13) 0 0
Cryotherapy 2 (5) 0 1 (8)
Amniotic membrane graft 1 (3) 1 (11) 0
Division of symblephara 1 (3) 0 0
Superficial keratectomy 1 (3) 0 0
Tectonic graft 0 1 (11) 0
aOther systemic medications, for SJS/TEN: IV immunoglobulins (7), ganciclovir (1), infliximab (1), meropenem (1), and vancomicin (1) at diagnosis;
IV immunoglobulins (1) and infliximab (1) at the time of follow-up.
bAmong OcMMP patients there was an increased use of lubricants since diagnosis, P¼ 0.008.
cOther topical medications: antibiotics (15), glaucoma therapy (2), autologous serum (1), cyclosporin (2), mitomicin (1), and sodium cromoglycate (1) at
diagnosis; antibiotics (5), glaucoma therapy (3), autologous serum (1), cyclosporin (2), mitomicin (1), retinoic acid (1), and sodium cromoglycate (1) at the
time of follow-up.
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oral mucosal biopsy). It is possible that reluctance to
perform a conjunctival biopsy was due to misplaced
concern about causing more damage before institution of
immunosuppression. We believe that if OcMMP is
suspected, biopsy of the conjunctiva, and tissue from
other sites of potential involvement, should be part of an
acceptable standard of care1 and with appropriate
precautions, bulbar conjunctival biopsy is safe.15 If
facilities do not exist for appropriate processing of biopsy
material, these patients should be referred to specialist
centres for diagnostic work-up.1 A range of
immunopathological (DIF, IIF) or histopathological
methods, may also support the diagnosis of other CC
disorders (Linear IgA disease, EBA, SS, AKC, OSSN).
Nonetheless, a critical caveat for the diagnosis of
immunobullous disease is the sensitivity and specificity
of currently available immunofluorescence techniques.
For OcMMP, a positive DIF result is found in 60–80% of
patients.1,16,17 The diagnosis of MMP in patients with the
typical phenotype of OcMMP, but with negative DIF, is a
current clinical issue; it has been suggested that biopsy-
negative patients should not be diagnosed as having
MMP.2 This recommendation leaves patients, who have
the typical phenotype and disease progression of
OcMMP, outside any current disease category resulting
in delayed diagnosis and treatment. We suggest that
rather than categorising biopsy-negative patients as
having some other unspecified disease, we recommend
that these patients should be accepted as presumed
MMP18 while efforts are made to improve the sensitivity
of existing diagnostic technologies, and to develop
novel alternative tools for diagnosis with improved
positive predictive values. Our proposed revision of
the immunopathological criteria for the diagnosis of
OcMMP are detailed in Table 5.
Management
A total of 32 of the 50 patients (64%) were given
immunosuppressive therapy after diagnosis, and 65%
continued to be on immunosuppression at follow up.
It is difficult to establish a figure for the proportion of
OcMMP patients who require immunosuppression as the
publications that describe large cohorts of patients have
focused on the use of immunosuppressive therapies for
the disease as a whole.19,20 However, in a series of 66
patients with a minimum of 2 years follow-up reported
in 1996,21 17/66 (26%) did not have inflammatory
disease considered severe enough to justify the risks
of immunosuppression, although this might not be the
case in a more contemporary case series.
The low proportions of patients in our current
paper treated with immunosuppressive therapy might
represent a reluctance to use this form of treatment
outside specialist centres. At follow-up, all groups
were shown to have a significant decrease in the
frequency of conjunctival inflammation, but even
with immunosuppression, fornix shrinkage progressed
in 17/66 (26%) of eyes with OcMMP. Although prognosis
is improved with systemic immunomodulation,12,19
Table 5 Proposed revised immunopathological criteria for the diagnosis of ocular mucous membrane pemphigoid
Consensus criteriaa 1. Direct immunofluorescence – presence of basement membrane zone (BMZ) deposits of IgG, IgA, IgM,
and/or C3.
K Detection of one or combination of the above linear epithelial BMZ immune deposits establishes the diagnosis
of autoimmune MMP.
K Patients with clinical manifestations similar or identical to MMP but in whom epithelial BMZ immune
deposits have not been demonstrated, these patients may be drug-induced or the pathogenesis of the disease
needs to be further elucidated.
2. Indirect immunofluorescence – presence of IgG and IgA autoantibodies binding to skin BMZ on salt split
epithelial substrate.
K Not all patients with MMP have detectable circulating autoantibodies to the basement membrane zone.
The consensus does not consider these findings to be an absolute criterion.
Proposed revised
criteria
Patients with a typical ocular phenotype of progressive conjunctival scarring consistent with a clinical diagnosis
of ocular mucous membrane pemphigoid PLUS either one of the following:
1. Positive conjunctival direct immunofluorescence or positive direct immunofluorescence from any other site
(eg, oral mucosa, skin) that meet the current consensus criteria.
Or
2. Negative direct immunofluorescence from any site and positive indirect immunofluorescence are diagnosed
as having MMP.
Or
3. Negative immunofluorescence studies (direct or indirect) only when other diseases that may cause this
phenotype have been excluded, are diagnosed as presumed OcMMP.
aChan et al.2
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it is important to note that up to 42% of patients
continue to demonstrate progressive conjunctival
scarring without clinically manifest inflammation.1,19
In addition, 24% of cases required oculoplastic surgery
to minimise secondary ocular surface inflammation
induced by deformed lids and misdirected lashes.
Summary
The overall minimum incidence of CC in the United
Kingdom is estimated as 1.3 per million. The proportion
of patients with CC having appropriate investigations
to confirm the disease is low, and the proportion of
OcMMP having immunosuppressive therapy is probably
less than optimal to prevent progression of disease,
which should be monitored objectively, with clearly
defined and validated activity and damage indices
of disease.1,22 Our data support the need for both
specialist oculoplastic and immunosuppression
treatment expertise, to appropriately manage patients
in the United Kingdom with CC.1 Currently, most
patients reside in the West Midlands, Yorkshire,
London, and the South East of the United Kingdom
where there is existing service provision for patients
with CC. Improved awareness within areas reporting
a low incidence of the disease, and better access to
designated specialist centres, can be expected to enable
delivery of the expert care that patients with these
diseases require if they are to receive optimal diagnostic
work-up and management.
Summary
What was known before
K Cicatrising conjunctivitis (CC) is a rare but sight-
threatening group of disorders for which early diagnosis
and appropriate treatment are essential.
K Most clinicians see few cases.
K There are no incidence data for conjunctival scarring
disorders in the United Kingdom.
What this study adds
K The overall minimum incidence of CC in the United
Kingdom is 1.3 per million with geographical
variance. There is a wide range in duration of
ocular symptoms (7–3650 days) before these diseases
are recognised.
K The use of appropriate investigations to confirm the
disease diagnosis is low. The proportion of patients
receiving optimal therapy to prevent progression of
disease is less than ideal.
K Objective assessment instruments with clearly defined
and validated activity and damage indices of disease are
required. Patients should be reviewed in dedicated
specialist centres with expertise in the diagnosis and
management of CC.
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